论文部分内容阅读
小鼠在分别接种EAC,HAC,ARS,L_(7712),L_(615)和S_(180)瘤细胞后,用剂量为7.5—30μgSe/鼠/次的SeO_2,Na_2SeO_3,NaHSeO_4,H_2SeO_3等硒化物进行抑瘤实验,结果证明,经腹腔注射给药对EAC,HAC,ARS等腹水型肿瘤都有显著的的抑瘤效应,各种硒化物之间没有明显的差别。经皮下注射SeO_2对EAC的抑制作用不明显。S_(180)经皮下同位注射较乏对侧位注射的抑制效果为好。据此可以认为硒化合物的抑瘤作用是由于硒对瘤细胞的直接杀伤所致,因此具有广谱的抑瘤效应。根据对实验小瘤的体重、肝、脾重量以及血相变化判断,在实验所用的剂量范围内,硒化物治疗的小鼠没有明显的毒性反应。本文还讨论了硒剂应用于临床的可能性问题。
After the mice were inoculated with EAC, HAC, ARS, L_(7712), L_(615) and S_(180) tumor cells, respectively, SeO2, Na_2SeO_3, NaHSeO_4, H_2SeO_3 and other selenium compounds were used at a dose of 7.5-30 μg Se/mouse/time. The experiment of tumor inhibition showed that the intraperitoneal injection had significant antitumor effect on EAC, HAC, ARS and other ascites tumors, and there was no significant difference among various selenides. Subcutaneous injection of SeO 2 had no obvious inhibitory effect on EAC. The S_(180) subcutaneous injection was less effective in suppressing lateral injections. Based on this, it can be considered that the anti-tumor effect of selenium compounds is due to the direct killing of selenium on tumor cells, so it has a broad-spectrum anti-tumor effect. According to the judgment of body weight, liver weight, spleen weight, and blood phase change of experimental nodules, there was no obvious toxic reaction in selenide-treated mice within the dose range used in the experiment. This article also discusses the possibility of applying selenium agents to the clinic.